34,659 XNAS Volume
XNAS 04 Apr, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Andrew Hull | Director | 11 Jan 2025 | 2 | 975 | - | - | Employee Stock Option (Expiration) | ||
| Johnson Aaron Shane | Sr VP & General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 1,500 | 3,900 | - | - | Employee Stock Option (Right to Buy) | |
| Lemerond Nicole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 550 | 975 | - | - | Employee Stock Option (Right to Buy) | |
| Hull Andrew | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 550 | 977 | - | - | Employee Stock Option (Right to Buy) | |
| A. Eric Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 6,250 | 14,300 | - | - | Employee Stock Option (Right to Buy) | |
| T. Bryan Baldasare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 550 | 975 | - | - | Employee Stock Option (Right to Buy) | |
| Jagpal N. Netta | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 3,750 | 6,250 | - | - | Employee Stock Option (Right to Buy) | |
| Hsu Eric C. | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 2,750 | 5,350 | - | - | Employee Stock Option (Right to Buy) | |
| Woudenberg Michael | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Dec 2024 | 3,750 | 7,505 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Consultant | Sale of securities on an exchange or to another person at price $ 0.18 per share. | 31 Jul 2024 | 240 | 0 | - | 0.2 | 42 | Common Stock |
| Michael Woudenberg | Chief Operating Officer | 27 May 2024 | 394 | 75,100 | - | - | Employee Stock Option (Expiration) | ||
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 27 May 2024 | 485 | 52,000 | - | - | Employee Stock Option (Expiration) | ||
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 27 May 2024 | 545 | 52,000 | - | - | Employee Stock Option (Expiration) | ||
| Eric A. Adams | Director, President & CEO | 27 May 2024 | 1,139 | 161,000 | - | - | Employee Stock Option (Expiration) | ||
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 04 Mar 2024 | 309 | 52,545 | - | - | Employee Stock Option (Expiration) | ||
| Andrew Hull | Director | Purchase of securities on an exchange or from another person at price $ 0.39 per share. | 21 Feb 2024 | 37,500 | 38,258 | - | 0.4 | 14,625 | Common Stock |
| Eric A. Adams | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.36 per share. | 20 Feb 2024 | 41,600 | 43,959 | - | 0.4 | 14,922 | Common Stock |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 21 Jan 2024 | 121 | 52,485 | - | - | Employee Stock Option (Expiration) | ||
| Andrew Hull | Director | 14 Jan 2024 | 42 | 8,542 | - | - | Employee Stock Option (Expiration) | ||
| Hsu C. Eric | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 45,000 | 52,854 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew Hull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 7,100 | 8,584 | - | - | Employee Stock Option (Right to Buy) | |
| Tegge Jonathan | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 30,000 | 31,400 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 45,000 | 52,606 | - | - | Employee Stock Option (Right to Buy) | |
| A. Eric Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 136,000 | 162,139 | - | - | Employee Stock Option (Right to Buy) | |
| Lemerond Nicole | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 7,100 | 8,500 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Woudenberg | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 65,000 | 75,494 | - | - | Employee Stock Option (Right to Buy) | |
| Aaron Shane Johnson | Sr VP & General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 40,000 | 48,000 | - | - | Employee Stock Option (Right to Buy) | |
| Baldasare T. Bryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2023 | 7,100 | 8,500 | - | - | Employee Stock Option (Right to Buy) | |
| Woudenberg Michael | Chief Operating Officer | 05 Dec 2023 | 848 | 10,494 | - | - | Employee Stock Option (Expiration) | ||
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 31 Aug 2023 | 327 | 7,854 | - | - | Employee Stock Option (Expiration) | ||
| Eric A. Adams | Director, President & CEO | 16 May 2023 | 1,818 | 26,139 | - | - | Employee Stock Option (Expiration) | ||
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 16 May 2023 | 152 | 8,181 | - | - | Employee Stock Option (Expiration) | ||
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 16 May 2023 | 485 | 7,606 | - | - | Employee Stock Option (Expiration) | ||
| Eric A. Adams | Director, President & CEO | 08 Mar 2023 | 545 | 27,957 | - | - | Employee Stock Option (Expiration) | ||
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | 08 Mar 2023 | 545 | 8,333 | - | - | Employee Stock Option (Expiration) | ||
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 08 Mar 2023 | 61 | 8,091 | - | - | Employee Stock Option (Expiration) | ||
| Sarah Li | VP Accounting & Controller | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 3,600 | 4,002 | - | - | Employee Stock Option (Right to Buy) | |
| Eric A. Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 15,000 | 28,502 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew Hull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 840 | 1,484 | - | - | Employee Stock Option (Right to Buy) | |
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 4,200 | 8,878 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 4,200 | 8,152 | - | - | Employee Stock Option (Right to Buy) | |
| Jonathan Tegge | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 1,400 | 1,400 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Woudenberg | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 7,500 | 11,342 | - | - | Employee Stock Option (Right to Buy) | |
| Bryan T. Baldasare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 840 | 1,400 | - | - | Employee Stock Option (Right to Buy) | |
| Shane Aaron Johnson | Sr VP & General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 4,200 | 8,000 | - | - | Employee Stock Option (Right to Buy) | |
| Nicole Lemerond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 840 | 1,400 | - | - | Employee Stock Option (Right to Buy) | |
| Eric A. Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 15,000 | 28,502 | - | - | Employee Stock Option (Right to Buy) | |
| Shane Aaron Johnson | Sr. VP & General Manager | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 4,200 | 8,000 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Woudenberg | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 7,500 | 11,342 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 4,200 | 8,152 | - | - | Employee Stock Option (Right to Buy) | |
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Nov 2022 | 4,200 | 8,878 | - | - | Employee Stock Option (Right to Buy) | |
| Nicole Lemerond | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 14,000 | 14,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 02 Jun 2022 | 1,515 | 98,787 | - | - | Employee Stock Option (Expiration) | ||
| Eric A. Adams | Director, President & CEO | 02 Jun 2022 | 13,636 | 337,576 | - | - | Employee Stock Option (Expiration) | ||
| Bryan T. Baldasare | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 May 2022 | 14,000 | 14,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eric A. Adams | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 14 Apr 2022 | 14,160 | 59,003 | - | 0.9 | 12,659 | Common Stock |
| Eric A. Adams | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 0.85 per share. | 13 Apr 2022 | 8,560 | 44,843 | - | 0.9 | 7,276 | Common Stock |
| Michael Woudenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 5,000 | 96,060 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 20 Feb 2022 | 3,030 | 100,302 | - | - | Employee Stock Option (Expiration) | ||
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | 24 Jan 2022 | 12,121 | 103,332 | - | - | Employee Stock Option (Expiration) | ||
| William J. Garner | Director | 24 Jan 2022 | 24,242 | 16,122 | - | - | Employee Stock Option (Expiration) | ||
| Bruce S. Colwill | CFO | Purchase of securities on an exchange or from another person at price $ 1.09 per share. | 24 Jan 2022 | 5,000 | 11,515 | - | 1.1 | 5,439 | Common Stock |
| Eric A. Adams | Director, President & CEO | 24 Jan 2022 | 60,606 | 411,818 | - | - | Employee Stock Option (Expiration) | ||
| Eric A. Adams | Director, President & CEO | 24 Jan 2022 | 60,606 | 351,212 | - | - | Employee Stock Option (Expiration) | ||
| Andrew Hull | Director | 24 Jan 2022 | 30,303 | 16,122 | - | - | Employee Stock Option (Expiration) | ||
| Adam D. Cutler | Director | 24 Jan 2022 | 22,727 | 16,122 | - | - | Employee Stock Option (Expiration) | ||
| Adam D. Cutler | Director | 24 Jan 2022 | 1,515 | 38,849 | - | - | Employee Stock Option (Expiration) | ||
| Adam D. Cutler | Director | 24 Jan 2022 | 6,061 | 40,364 | - | - | Employee Stock Option (Expiration) | ||
| Shane Aaron Johnson | SVP, GM of BayMedica LLC | Purchase of securities on an exchange or from another person at price $ 1.26 per share. | 06 Jan 2022 | 8,500 | 304,595 | - | 1.3 | 10,710 | Common Stock |
| Shane Aaron Johnson | SVP, GM of BayMedica LLC | Purchase of securities on an exchange or from another person at price $ 1.33 per share. | 30 Dec 2021 | 8,093 | 296,095 | - | 1.3 | 10,736 | Common Stock |
| William J. Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 40,364 | - | - | Employee Stock Option (Right to Buy) | |
| Catherine A. Sazdanoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 29,091 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew Hull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 46,425 | - | - | Employee Stock Option (Right to Buy) | |
| Adam D. Cutler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2021 | 7,000 | 46,425 | - | - | Employee Stock Option (Right to Buy) | |
| Shane Aaron Johnson | SVP, GM of BayMedica LLC | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 15 Nov 2021 | 5,000 | 288,002 | - | 1.4 | 6,845 | Common Stock |
| Eric A. Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 125,000 | 472,424 | - | - | Employee Stock Option (Right to Buy) | |
| Bruce S. Colwill | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 60,000 | 150,303 | - | - | Employee Stock Option (Right to Buy) | |
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 35,000 | 116,969 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 35,000 | 115,453 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Woudenberg | VP, Chem/Manufacturing/Control | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2021 | 30,000 | 91,060 | - | - | Employee Stock Option (Right to Buy) | |
| Eric A. Adams | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.73 per share. | 29 Sep 2021 | 8,800 | 36,283 | - | 1.7 | 15,224 | Common Stock |
| Bruce S. Colwill | CFO | Purchase of securities on an exchange or from another person at price $ 1.77 per share. | 28 Sep 2021 | 5,000 | 6,515 | - | 1.8 | 8,840 | Common Stock |
| Eric A. Adams | Director, President & CEO | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 28 Sep 2021 | 11,400 | 27,483 | - | 1.8 | 19,984 | Common Stock |
| William J. Garner | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Michael Woudenberg | VP, Chem/Manufacturing/Control | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 30,000 | 30,000 | - | - | Employee Stock Option (Right to Buy) | |
| Alexandra D.J. Mancini | Sr VP, Clinical Reg Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eric C. Hsu | Sr. VP, Pre-Clinical Res/Dev | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 35,000 | 35,000 | - | - | Employee Stock Option (Right to Buy) | |
| Adam D. Cutler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew Hull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Eric A. Adams | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 125,000 | 125,000 | - | - | Employee Stock Option (Right to Buy) | |
| Catherine A. Sazdanoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 7,000 | 7,000 | - | - | Employee Stock Option (Right to Buy) | |
| Catherine A. Sazdanoff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 11,000 | 11,000 | - | - | Employee Stock Option (Right to Buy) | |
| Bruce S. Colwill | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2020 | 60,000 | 60,000 | - | - | Employee Stock Option (Right to Buy) |